Biological differences in depression and anxiety across races and ethnic groups

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 13, 2001, Pages 13-21

  Lin, K M ^a   Nutt, ^a   Ballenger, ^a   Kirmayer, ^a   Tajima, ^a   Davidson, ^a   Lepine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CODEINE; DESIPRAMINE; DEXAMETHASONE; DIAZEPAM; DILTIAZEM; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; METHYLDOPA; MEVINOLIN; MIDAZOLAM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NIFEDIPINE; NIMODIPINE; NORCLOMIPRAMINE; NORTRIPTYLINE; OPIATE; PAROXETINE; PERPHENAZINE; PROPRANOLOL; PSYCHOTROPIC AGENT; QUETIAPINE; QUINIDINE SULFATE; RISPERIDONE; SERTINDOLE; SERTRALINE; THIORIDAZINE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM;

ANXIETY NEUROSIS; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ETHNIC DIFFERENCE; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RACE DIFFERENCE; REVIEW;

ANXIETY DISORDERS; CONTINENTAL POPULATION GROUPS; CROSS-CULTURAL COMPARISON; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; ELECTROENCEPHALOGRAPHY; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROCORTISONE; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; SLEEP; SLEEP, REM;

EID: 0034973616     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Abnormal electroencephalographic sleep profiles in major depression: Association with response to cognitive behavior therapy
2. Sleep research in depressive illness: Clinical implications - A tasting menu
3. Epidemiology, burden, and disability in depression and anxiety
4. Sleep electroencephalography in depressive illness: A collaborative study by the World Health Organization
5. EEG sleep in African-American patients with major depression: A historical case control study
6. Relationship between ethnicity and sleep patterns in normal controls: Implications for psychopathology and treatment
7. REM sleep in depression is influenced by ethnicity
8. Biological markers as classifiers for depression: A multivariate study
9. The DST in a large outpatient clinic: Its diagnostic and predictive significance
10. Neuroendocrine aspects of primary endogenous depression, 2: Serum dexamethasone concentrations and hypothalamic-pituitary-adrenal cortical activity as determinants of the dexamethasone suppression test response
11. Racial and ethnic factors in psychiatric research
12. Does ethnicity affect DST results?
13. Depression, weight loss and the dexamethasone suppression test
14. Lithium treatment in affective disorders: Therapeutic plasma level
15. Tricyclic antidepressants: Therapeutic plasma level
16. Neuroleptic dosage for Asians
17. Dose-response variation among different populations
18. Haloperidol and prolactin concentrations in Asians and Caucasians
19. Nortriptyline kinetics in Japanese and Americans
20. Ethnic differences in drug response
21. Lithium pharmacokinetics: Inter-racial comparison
22. The first lithium clinic in Hong Kong: A Chinese profile
23. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients
24. Pharmacogenetics of alcohol metabolism and alcoholism
25. Apparent monomorphism of ALDH2 in seven American Indian populations
26. Aldehyde dehydrogenase polymorphism in North American, South American, and Mexican Indian populations
27. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
28. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYF2D6
29. Venlafaxine serum levels and CYP2D6 genotype
30. Pharmacogenetics and drug metabolism of newer antidepressant agents
31. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine
32. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
33. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
34. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
35. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
36. Factors affecting the absolute bioavailability of nifedipine
37. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians
38. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers
39. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations in alcohol-dependent subjects
40. Serotonin transporter candidate gene studies in affective disorders and personality: Promises and potential pitfalls
41. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers
42. 2 dopamine receptor gene and alcoholism: A tempest in a wine cup?
43. 2 receptor locus
44. 2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: A lung cancer case-control study
45. Ethnic differences in catechol O-methyltransferase pharmacogenetics: Frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals
46. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles
47. Catechol-O-methyltransferase activity and classification of depression
48. COMT and DRD3 polymorphisms, environmental exposures, and personality traits related to common mental disorders
49. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study
50. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity
51. High rates of schizophrenia in adults with velo-cardio-facial syndrome
52. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
53. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
54. Serotonin transporter gene polymorphism and antidepressant response